Cross-platform comparison of microarray-based multiple-class prediction.
High-throughput microarray technology has been widely applied in biological and medical decision-making research during the past decade. However, the diversity of platforms has made it a challenge to re-use and/or integrate datasets generated in different experiments or labs for constructing array-based diagnostic models. Using large toxicogenomics datasets generated using both Affymetrix and Agilent microarray platforms, we carried out a benchmark evaluation of cross-platform consistency in multiple-class prediction using three widely-used machine learning algorithms. After an initial assessment of model performance on different platforms, we evaluated whether predictive signature features selected in one platform could be directly used to train a model in the other platform and whether predictive models trained using data from one platform could predict datasets profiled using the other platform with comparable performance. Our results established that it is possible to successfully apply multiple-class prediction models across different commercial microarray platforms, offering a number of important benefits such as accelerating the possible translation of biomarkers identified with microarrays to clinically-validated assays. However, this investigation focuses on a technical platform comparison and is actually only the beginning of exploring cross-platform consistency. Further studies are needed to confirm the feasibility of microarray-based cross-platform prediction, especially using independent datasets.
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Xiaohui
X
Fan
Li
L
Shao
Hong
H
Fang
Weida
W
Tong
Yiyu
Y
Cheng
D000465:Algorithms; D001185:Artificial Intelligence; D003625:Data Collection; D030541:Databases, Genetic; D057166:High-Throughput Screening Assays; D046228:Microarray Analysis; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D012107:Research Design; D043922:Toxicogenetics / Q000295:instrumentation / Q000379:methods
Nucleic Acids Res. 2000 Nov 15;28(22):4552-7
11071945
BMC Bioinformatics. 2002 Aug 23;3:22
12194703
Environ Mol Mutagen. 2007 Jun;48(5):380-94
17370338
BMC Genomics. 2008 Jun 16;9:288
18558008
Lancet. 2005 May 14-20;365(9472):1683; author reply 1684-5
15894091
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Curr Opin Biotechnol. 2008 Feb;19(1):10-8
18155896
Nucleic Acids Res. 2002 May 15;30(10):e48
12000853
Nat Biotechnol. 2006 Sep;24(9):1151-61
16964229
Nat Rev Genet. 2008 Apr;9(4):291-302
18347592
Clin Cancer Res. 2010 Jan 15;16(2):629-36
20068095
J Natl Cancer Inst. 2003 Jan 1;95(1):14-8
12509396
J Bioinform Comput Biol. 2009 Feb;7(1):157-73
19226665
Nucleic Acids Res. 2003 Oct 1;31(19):5676-84
14500831
Nat Genet. 2003 Jan;33(1):90-6
12469123
Toxicol Pathol. 2006;34(7):921-8
17178692
Nat Biotechnol. 2001 Apr;19(4):342-7
11283592
J Theor Biol. 2006 May 7;240(1):9-13
16197963
Drug Discov Today. 2009 Apr;14(7-8):337-42
19340928
Genome Biol. 2008;9(6):R100
18570634
Bioinformatics. 2002 Mar;18(3):405-12
11934739
Am J Pathol. 2007 Aug;171(2):375-85
17600117
Nat Biotechnol. 2006 Sep;24(9):1162-9
17061323
Environ Health Perspect. 2004 Aug;112(12):1236-48
15345370
BMC Bioinformatics. 2005 Jul 15;6 Suppl 2:S12
16026597
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507
17255271
Pharmacogenomics J. 2010 Aug;10(4):247-57
20676064